Yunya Luo

Central South University — China

Medicine · Health Sciences

10h-index306citations26works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(9), Histone Deacetylase Inhibitors Research(6), Chronic Myeloid Leukemia Treatments(4), Immunotherapy and Immune Responses(3), Multiple Myeloma Research and Treatments(3)

Publications26 total

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial
Blood·2025Open Access
Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial
Blood·2025Open Access
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study
British Journal of Haematology·2025
7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
Blood·2024Open Access
Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
Blood·2024· 1 cited
Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
Blood·2024Open Access
Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial
Blood·2024
Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with <i>De Novo</i> Acute Myeloid Leukemia
Blood·2024· 1 cited
High Efficacy and Tolerability of Daratumumab-Based Regimens in First-Line Treatment of Patients with Immunoglobulin Light Chain Amyloidosis: A Real-World Evidence Analysis
SSRN Electronic Journal·2024Open Access
Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia
Blood·2023· 1 citedOpen Access
Proteomic profiling of plasma exosomes from patients with B-cell acute lymphoblastic leukemia
Scientific Reports·2022· 14 citedOpen Access
LncRNA-NEAT1 promotes proliferation of T-ALL cells via miR-146b-5p/NOTCH1 signaling pathway
Pathology - Research and Practice·2020· 17 cited
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1− pre-B-ALL
Cell Death and Disease·2020· 13 citedOpen Access
A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction
Annals of Hematology·2020· 21 cited
A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2V617F and confers a proliferative potential on erythroid lineages
Oncotarget·2016· 9 citedOpen Access
Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3
Oncotarget·2015· 83 citedOpen Access
Deregulation of Mitochondrial ATPsyn-β in Acute Myeloid Leukemia Cells and with Increased Drug Resistance
PLoS ONE·2013· 20 citedOpen Access
An Intron Mutation in the ACVRL1 May Be Associated with a Transcriptional Regulation Defect in a Chinese Family with Hereditary Hemorrhagic Telangiectasia
PLoS ONE·2013· 12 citedOpen Access
Decreased 5-hydroxymethylcytosine levels are associated with<i>TET2</i>mutation and unfavorable overall survival in myelodysplastic syndromes
Leukemia & lymphoma/Leukemia and lymphoma·2013· 50 cited
Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination
Haemophilia·2011· 38 cited
page 1 of 2Next →

Frequent Co-authors

Hongling Peng(15), Guangsen Zhang(11), Xingli Zhao(9), Xiaohui Suo(9), Xinxiao Lu(9), Congcong Zhang(9), Yaxian Tan(9), Guanchen Bai(9), Pengxiang Guo(9), Zeping Zhou(8), Sifeng Gao(8), Yanliang Bai(7), Linyu Yuan(7), Yinling Li(7), Yingchang Mi(7), Kaiqi Liu(7), Sufang Liu(6), Ruijuan Li(5), Yunxiao Xu(5), Jilei Zhang(5)